Page last updated: 2024-09-02

morpholinoanthracycline mx2 and decitabine

morpholinoanthracycline mx2 has been researched along with decitabine in 1 studies

Compound Research Comparison

Studies
(morpholinoanthracycline mx2)
Trials
(morpholinoanthracycline mx2)
Recent Studies (post-2010)
(morpholinoanthracycline mx2)
Studies
(decitabine)
Trials
(decitabine)
Recent Studies (post-2010) (decitabine)
531503,8042052,177

Protein Interaction Comparison

ProteinTaxonomymorpholinoanthracycline mx2 (IC50)decitabine (IC50)
DNA (cytosine-5)-methyltransferase 1Homo sapiens (human)0.03

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adachi, M; Asano, T; Fujii, H; Fukunaga, Y; Hasegawa, K; Horichi, N; Isoe, T; Nakamura, K; Ohmori, T; Otake, N1

Other Studies

1 other study(ies) available for morpholinoanthracycline mx2 and decitabine

ArticleYear
Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation.
    British journal of cancer, 2005, Apr-25, Volume: 92, Issue:8

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Blotting, Northern; Carubicin; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Humans; Immunoblotting; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger

2005